Abstract
ObjectiveExisting randomized controlled trials and metanalyses suggest that IVF cycle outcomes of GnRH antagonist and agonist cycles may be comparable. Potential benefits of GnRH antagonist cycles compared to GnRH agonist cycles include reductions in total medication administered, length of cycle, and adverse effects including hot flashes and ovarian hyperstimulation syndrome. Specifically, the role of cycle length in GnRH antagonist cycles is not known. We aimed to examine the relationship between length of gonadotropin stimulation and outcomes in GnRH antagonist IVF cycles.DesignRetrospective data analysis.Materials and methodsWe utilized our program’s database to review all IVF cycles in which a GnRH antagonist (cetrorelix) was used. Cycles were divided into two groups: length of stimulation < 8 days and ≥ 8 days. Differences between the groups were evaluated with the Student’s t-test for continuous variables and the chi-square test for categorical or dichotomous variables. A subgroup analysis of ICSI cycles was conducted.ResultsTabled 1ConclusionsOur retrospective analysis of 2,033 GnRH antagonist IVF cycles demonstrated that length of stimulation is not associated with a significant difference in pregnancy rates. In particular, except for having a reduced chance of being able to freeze excess embryos, a short stimulation cycle is not detrimental to the ultimate outcome of that treatment cycle. ObjectiveExisting randomized controlled trials and metanalyses suggest that IVF cycle outcomes of GnRH antagonist and agonist cycles may be comparable. Potential benefits of GnRH antagonist cycles compared to GnRH agonist cycles include reductions in total medication administered, length of cycle, and adverse effects including hot flashes and ovarian hyperstimulation syndrome. Specifically, the role of cycle length in GnRH antagonist cycles is not known. We aimed to examine the relationship between length of gonadotropin stimulation and outcomes in GnRH antagonist IVF cycles. Existing randomized controlled trials and metanalyses suggest that IVF cycle outcomes of GnRH antagonist and agonist cycles may be comparable. Potential benefits of GnRH antagonist cycles compared to GnRH agonist cycles include reductions in total medication administered, length of cycle, and adverse effects including hot flashes and ovarian hyperstimulation syndrome. Specifically, the role of cycle length in GnRH antagonist cycles is not known. We aimed to examine the relationship between length of gonadotropin stimulation and outcomes in GnRH antagonist IVF cycles. DesignRetrospective data analysis. Retrospective data analysis. Materials and methodsWe utilized our program’s database to review all IVF cycles in which a GnRH antagonist (cetrorelix) was used. Cycles were divided into two groups: length of stimulation < 8 days and ≥ 8 days. Differences between the groups were evaluated with the Student’s t-test for continuous variables and the chi-square test for categorical or dichotomous variables. A subgroup analysis of ICSI cycles was conducted. We utilized our program’s database to review all IVF cycles in which a GnRH antagonist (cetrorelix) was used. Cycles were divided into two groups: length of stimulation < 8 days and ≥ 8 days. Differences between the groups were evaluated with the Student’s t-test for continuous variables and the chi-square test for categorical or dichotomous variables. A subgroup analysis of ICSI cycles was conducted. ResultsTabled 1 ConclusionsOur retrospective analysis of 2,033 GnRH antagonist IVF cycles demonstrated that length of stimulation is not associated with a significant difference in pregnancy rates. In particular, except for having a reduced chance of being able to freeze excess embryos, a short stimulation cycle is not detrimental to the ultimate outcome of that treatment cycle. Our retrospective analysis of 2,033 GnRH antagonist IVF cycles demonstrated that length of stimulation is not associated with a significant difference in pregnancy rates. In particular, except for having a reduced chance of being able to freeze excess embryos, a short stimulation cycle is not detrimental to the ultimate outcome of that treatment cycle.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call